934 results on '"Herbrecht, Raoul"'
Search Results
102. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation
103. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital
104. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
105. Apports des dérivés lipidiques de l’amphotéricine B dans la prise en charge des infections fongiques
106. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
107. Poly(ADP‐ribose)polymerase inhibitors‐associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.
108. Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH
109. Fungal Infections in Patients With Neutropenia: Challenges in Prophylaxis and Treatment
110. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
111. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. (Major Article)
112. CHOP chemotherapy plus rituximab compared wiht CHOP alone in elderly patients with diffuse largeB-cell lymphoma
113. Pharmacokinetic drug–drug interactions with methotrexate in oncology
114. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
115. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients
116. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease
117. Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis
118. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID‐19 and acute promyelocytic leukaemia
119. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry
120. Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center
121. Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP‐EBMT, EORTC‐IDG and SEIFEM survey
122. Validation by Real-life Data of the New Radiological Criteria of the Revised and Updated Consensus Definition for Invasive Fungal Diseases
123. Invasive Pulmonary Aspergillosis
124. Antifungal Therapy: New and Evolving Therapies
125. Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine
126. Cola beverage and delayed elimination of methotrexate
127. Lessons from a Case of Oromandibular Mucormycosis Treated with Surgery and a Combination of Amphotericin B Lipid Formulation plus Caspofungin
128. Correction for Cornu et al., “Evaluation of Mass Spectrometry-Based Detection of Panfungal Serum Disaccharide for Diagnosis of Invasive Fungal Infections: Results from a Collaborative Study Involving Six European Clinical Centers”
129. Risk factors and mortality in invasive Rasamsonia spp. infection: Analysis of cases in the FungiScope ® registry and from the literature
130. A Core Proliferative Program Induced By B-Cell Receptor Stimulation in Chronic Lymphocytic Leukemia Cells
131. Methylprednisolone‐induced immune thrombocytopenia
132. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
133. An atypical cause of dyspnea
134. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients
135. Changes in Causes of Death Over Time After Treatment for Invasive Aspergillosis
136. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®
137. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: A randomized pilot study (Combistrat trial)
138. [18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography for Early Evaluation of Treatment Efficacy in Advanced Non-Hodgkin Lymphoma of Uterine Corpus: A Case Report
139. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis
140. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen
141. Can combination salvage therapy for invasive aspergillosis improve patient outcome?
142. Voriconazole: therapeutic review of a new azole antifungal
143. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998–1999
144. Invasive Pulmonary Aspergillosis
145. Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study
146. Caspofungin: the first representative of a new antifungal class
147. Voriconazole versus Amphotericin B for Invasive Aspergillosis
148. Aspergillus Galactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients
149. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
150. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.